References
- Plouin PF, Reti E, Magin SG. Efficacy and safety of candesartan cilexetil in combination with hydrochlorothiazide in the treatment of patients with mild to moderate hypertension unresponsive to hydrochlorothiazide alone. Am J Hypertens 1997;10(4):90A
- Öhman P, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydro-chlorothiazide in insufficiently controlled primary hypertension – a comparison with a combination of losartan and hydro-chlorothiazide. Blood Press 2000;9:214–20
- Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydro-chlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: Results of the CARLOS study. Clin Drug Invest 2000;19(4):239–46
- Oparil S, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Am J Cardiol 1999;84:289–93
- Oparil S. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. Am J Cardiol 1999;84:35–41
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
- Easthope SE, Jarvis B. Candesartan cilexetil – an update of its use in essential hypertension. Drugs 2002;62:1253–87
- Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination. A review of its use in hypertension. Drugs 2002;62:787–816
- Chalmers J, et al. (WHO–ISH Hypertension Guidelines Committee). International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151–85
- Karlberg BE, Andrup M, Odén A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil, as compared to monotherapy in primary hypertension. Blood Press 2000;9:140–5
- Guidelines Committee. European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53
- MacGregor GA, Antonios TF, He FJ. The efficacy of an angiotensin II antagonist in moderate to severe hypertension – a double-blind withdrawal study. Hypertension 2000;36:454–60
- Gradman A, Arcuri KE, Goldberg AI, et al. A randomised, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345–50
- Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997;6: 35–43
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:837–46
- Philipp T, Letzel H, Ahrens H-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997;11\(Suppl. 2):S61–S68